A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations

Determination of the Sun Protection Factor (SPF) and in Vitro UVA Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations

The purpose of this study is to determine the SPF and UVAPF of four sunscreen formulations using international standard methodologies ISO24444:2010 for SPF and ISO24443:2012 for UVAPF.

Study Overview

• Status: Completed
• Conditions: Sunscreening Agents
• Intervention / Treatment: Other: P3 Standard, (Expected SPF 16); Other: NGBUV000A, (Expected SPF 30); Other: NGBUV000B, (Expected SPF 30); Other: NGBUV000C, (Expected SPF 30); Other: NGBUV000D, (Expected SPF 30); Other: Sunscreen formulation S2; Other: Glycerin

Detailed Description

This study consist of two steps. Step 1: determination of the SPF of the test products which will be performed as a single-center, randomized, evaluator blind, intra-individual comparison, no treatment and positive controlled clinical study as per ISO24444:2010. And Step 2: determination of the UVAPF of the test products which will be performed as a single center, open-label, negative and positive controlled technical test as per ISO24443:2012 (using test plates for assessing UV transmittance of four developmental sunscreens).

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Schleswig-Holstein
    • Schenefeld, Schleswig-Holstein, Germany, 22869
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
• Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination
• Participants with a Fitzpatrick Skin Type of I, II or III
• Participants with an Individual Typology Angle (ITA°) greater than 28°

Exclusion Criteria:

• Women who are known to be pregnant or who are intending to become pregnant over the duration of the study
• Women who are breast-feeding or lactating
• Participants having used medication with known photo-toxic and/or photosensitizing potential (e.g. hypericum perforatum, antibiotics, blood pressure regulating agents) up to 14 days prior to screening
• Participants with a history of systemic therapy with anti-inflammatory agents or analgesics (e.g. diclofenac) up to 3 days prior to screening
• Participants with dermatological conditions
• Participants with a history of abnormal response to the sun
• Participants having marks, blemishes or nevi or presenting existing sun damage in the test area
• Participants having excessive hair, moles, tattoos, scars or other imperfections in the test area that could influence the investigation
• Participants with a history of systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. anti-allergics) up to 7 days prior to screening
• Participants with a non-uniform skin colour or hyperpigmentation in the test area
• Participants with a medical history of dysplastic nevi or melanoma
• Participants with one of the following illnesses that might require regular systemic medication: Insulin-dependent diabetes, cancer
• Participants with asthma, unless medicated
• Participants with an electronic implant (e.g. pace maker, insulin pump, hearing aid) that cannot be removed during irradiation
• AIDS (acquired immune deficiency syndrome) and infectious hepatitis, if known to the participants
• Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
• Known allergy to latex
• Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days prior to screening
• Participation in another clinical study involving UV exposure to the same test site up to 2 months prior to screening
• Previous participation in this study
• Recent history (within the last 5 years) of alcohol or other substance abuse
• Participants who have used a tanning bed or other tanning treatment on the back area up to 1 month prior to screening
• Participants accustomed to using tanning beds
• Participants who have used self-tanning products on the back area in the previous 1 month prior to screening
• An employee of the sponsor or the study site or members of their immediate family

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Reference product (for SPFi calculation); This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.	Other: P3 Standard, (Expected SPF 16); A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
Experimental: Test product 1; This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.	Other: NGBUV000A, (Expected SPF 30); A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
Experimental: Test product 2; This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.	Other: NGBUV000B, (Expected SPF 30); A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
Experimental: Test product 3; This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.	Other: NGBUV000C, (Expected SPF 30); A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
Experimental: Test product 4; This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.	Other: NGBUV000D, (Expected SPF 30); A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
No Intervention: Negative control (for SPFi calculation); This arm will include all the test sites on the participants back which will be left unprotected.
Active Comparator: Reference (for UVAPFi calculation); This arm will include test plates treated with reference sunscreen formulation S2.	Other: Sunscreen formulation S2; A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
Other: Blank control (for UVAPFi calculation); This arm will include blank test plates treated with glycerin.	Other: Glycerin; A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values	Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hours after exposure to ultraviolet (UV) radiation. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome.The provisional MEDu was the lowest dose of UV radiation that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UV exposure.Higher values represents increased SPF protection.	Up to 24 hours post UV exposure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Spectrum of Sun Protection	Broad spectrum of sun protection was calculated by the ratio of the arithmetic mean of SPF to the arithmetic mean of UVAPF. Higher values represents increased SPF protection.	Up to 30 minutes post UV exposure

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): June 21, 2017
• Primary Completion (Actual): July 7, 2017
• Study Completion (Actual): July 7, 2017

Study Registration Dates

• First Submitted: May 16, 2017
• First Submitted That Met QC Criteria: May 16, 2017
• First Posted (Actual): May 17, 2017

Study Record Updates

• Last Update Posted (Actual): July 22, 2019
• Last Update Submitted That Met QC Criteria: May 17, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Protective Agents; Dermatologic Agents; Radiation-Protective Agents; Cryoprotective Agents; Glycerol; Sunscreening Agents
• Other Study ID Numbers: 207583

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No